Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30348538

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Nov
First author
Robak T

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Nov;19(11):1419-1421. doi: 10.1016/S1470-2045(18)30743-5.
    note
    Source null
    related pmid
    30348536
    relationship
    Comment in

Authors and identifiers

  1. name
    Robak T
    type
    Author
  2. name
    Jin J
    type
    Author
  3. name
    Pylypenko H
    type
    Author
  4. name
    Verhoef G
    type
    Author
  5. name
    Siritanaratkul N
    type
    Author
  6. name
    Drach J
    type
    Author
  7. name
    Raderer M
    type
    Author
  8. name
    Mayer J
    type
    Author
  9. name
    Pereira J
    type
    Author
  10. name
    Tumyan G
    type
    Author
  11. name
    Okamoto R
    type
    Author
  12. name
    Nakahara S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Robak T
    type
    Author
  2. name
    Jin J
    type
    Author
  3. name
    Pylypenko H
    type
    Author
  4. name
    Verhoef G
    type
    Author
  5. name
    Siritanaratkul N
    type
    Author
  6. name
    Drach J
    type
    Author
  7. name
    Raderer M
    type
    Author
  8. name
    Mayer J
    type
    Author
  9. name
    Pereira J
    type
    Author
  10. name
    Tumyan G
    type
    Author
  11. name
    Okamoto R
    type
    Author
  12. name
    Nakahara S
    type
    Author
bibliography ids
  1. nci-bib-fe05a7e800183833680460ff
book metadata
content sha256
e8cef173b714fe0f6ea389b67adb343f6868d82b92218810acea7c9a5b88cd90
document type
citation
dois
  1. 10.1016/S1470-2045(18)30685-5
electronic publication date
display
2018 Oct 19
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:30348538
immutable id
pubmed:30348538@e8cef173b714fe0f6ea389b67adb343f6868d82b92218810acea7c9a5b88cd90
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
11
name
The Lancet. Oncology
nlm unique id
100957246
pages
1449-1458
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Nov;19(11):1419-1421. doi: 10.1016/S1470-2045(18)30743-5.
    note
    Source null
    related pmid
    30348536
    relationship
    Comment in
outcomes validated
false
pmid
30348538
provenance
batch id
438b2803888025c6cf56
provider
NCBI PubMed ESummary
record sha256
09313206493e716e83c0d6465a9e9727131137ff086ee35bf140df64c828f845
response sha256
0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
retrieved at
2026-09-09T23:47:36.359220+00:00
publication date
display
2018 Nov
precision
month
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30348538/
title
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.

Preserved source evidence · Not medical advice